FindTrial
Sign In

CIDP07 Rozanolixizumab Post Trial Access Program (the PTA)

CIDP07 Rozanolixizumab Post Trial Access Program (the PTA)

Status
NO_LONGER_AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT05014724
Enrollment
Unknown
Registered
2021-08-20
Start date
Unknown
Completion date
Unknown
Last updated
2024-01-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Keywords

Chronic inflammatory demyelinating polyradiculoneuropathy, CIDP, UCB7665, rozanolixizumab

Brief summary

This Post Trial Access (PTA) Program enables access to rozanolixizumab for eligible patients who have taken part in the CIDP04 trial (NCT04051944) and are continuing to derive benefit from treatment.

Interventions

DRUGRozanolixizumab

Rozanolixizumab is dosed weekly. Patients should continue to receive the dose they were receiving in the CIDP04 (NCT04051944) trial.

Sponsors

UCB Biopharma SRL
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* Patient who has taken part in the CIDP04 (NCT04051944) study * Patient who derives continued benefit from treatment * All required safety information has been reported as per local laws/regulations, reported to Bionical, as appropriate, and documented in the patient's medical records * Patient is not pregnant

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026